{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T16:59:20Z","timestamp":1784221160580,"version":"3.55.0"},"reference-count":34,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n<jats:title>Background\/Introduction:<\/jats:title>\n<jats:p>Lipid nanoparticles (LNPs) are one of the most clinically\nadvanced candidates for delivering nucleic acids to target cell populations, such as hepatocytes.\nOnce LNPs are endocytosed, they must release their nucleic acid cargo into the cell cytoplasm. For\ndelivering messenger RNA (mRNA), delivery into the cytosol is sufficient; however, for delivering\nDNA, there is an added diffusional barrier needed to facilitate nuclear uptake for transcription\nand therapeutic effect.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>The objective of the presented study was to use fluorescence microscopy to identify\nnucleic acid localization to endosomes and lysosomes after escape from lipid nanoparticles in\norder to optimize lipid nanoparticle formulations.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Here, we use fluorescence microscopy to investigate the intracellular fate of different\nLNP formulations to determine the kinetics of localization to endosomes and lysosomes. LNPs\nused in the studies were prepared via self-assembly using a NanoAssemblr for microfluidic mixing.\nAs the content of polyethylene glycol (PEG) within the LNP formulation influences cellular\nuptake by hepatocyte cells, the content and hydrocarbon chain length within the formulation were\nassessed for their impact on intracellular trafficking. Standard LNPs were then formed using three\ncommercially available ionizable lipids, Dlin-MC3-DMA (MC3), Dlin-KC2-DMA (KC2), and\nSS-OP. Plasmid DNA (pDNA) and mRNA were used, more specifically with a mixture of Cyanine\n3 (Cy3)-labeled and green fluorescence protein (GFP) producing plasmid DNA (pDNA) as\nwell as Cy5-labeled GFP producing mRNA. After formulation, LNPs were characterized for the\nencapsulation efficiency of the nucleic acid, hydrodynamic diameter, polydispersity, and zeta potential.\nAll standard LNPs were ~100 nm in diameter and had neutral surface charge. All LNPs\nresulted in encapsulation efficiency greater than 70%. Confocal fluorescence microscopy was used\nfor the intracellular trafficking studies, where LNPs were incubated with HuH-7 hepatocyte cells\nat times ranging from 0-48 h. The cells were antibody-stained for subcellular components, including\nnuclei, endosomes, and lysosomes.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Analysis was performed to quantify localization of pDNA to the endosomes and lysosomes.\nLNPs with 1.5 mol% PEG and a hydrocarbon chain C14 resulted in optimal endosomal\nescape and GFP production. Results from this study demonstrate that a higher percentage of C14\nPEG leads to smaller LNPs with limited available phospholipid binding area for ApoE, resulting in\ndecreased cellular uptake. We observed differences in the localization kinetics depending on the\nLNP formulation type for SS-OP, KC2, and MC3 ionizable lipids. The results also demonstrate the\ntechnique across different nucleic acid types, where mRNA resulted in more rapid and uniform\nGFP production compared to pDNA delivery.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Here, we demonstrated the ability to track uptake and the sub-cellular fate of LNPs\ncontaining pDNA and mRNA, enabling improved screening prior to in vivo studies which would\naid in formulation optimization.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1389201024666230403094238","type":"journal-article","created":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T04:48:02Z","timestamp":1680670082000},"page":"102-112","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Intracellular Trafficking Kinetics of Nucleic Acid Escape from Lipid\nNanoparticles via Fluorescence Imaging"],"prefix":"10.2174","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5655-1002","authenticated-orcid":true,"given":"Christina M.","family":"Bailey-Hytholt","sequence":"first","affiliation":[{"name":"Genomic Medicines and Biologics Drug Product Development, Global CMC, Sanofi, Framingham, Massachusetts,\nUSA"},{"name":"Department of Chemical Engineering, Worcester Polytechnic Institute, Worcester, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Ulinski","sequence":"additional","affiliation":[{"name":"Department of Global Discovery Pathology, Sanofi, Framingham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Dugas","sequence":"additional","affiliation":[{"name":"Genomic Medicines and Biologics Drug Product Development, Global CMC, Sanofi, Framingham, Massachusetts,\nUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Haines","sequence":"additional","affiliation":[{"name":"Genomic Medicines and Biologics Drug Product Development, Global CMC, Sanofi, Framingham, Massachusetts,\nUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihael","family":"Lazebnik","sequence":"additional","affiliation":[{"name":"Genomic Medicines and Biologics Drug Product Development, Global CMC, Sanofi, Framingham, Massachusetts,\nUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Piepenhagen","sequence":"additional","affiliation":[{"name":"Department of Global Discovery Pathology, Sanofi, Framingham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isidro E.","family":"Zarraga","sequence":"additional","affiliation":[{"name":"Genomic Medicines and Biologics Drug Product Development, Global CMC, Sanofi, Framingham, Massachusetts,\nUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amey","family":"Bandekar","sequence":"additional","affiliation":[{"name":"Genomic Medicines and Biologics Drug Product Development, Global CMC, Sanofi, Framingham, Massachusetts,\nUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41573-020-0090-8","volume":"20","author":"Mitchell M.J.","year":"2021","unstructured":"Mitchell M.J.; Billingsley M.M.; Haley R.M.; Wechsler M.E.; Peppas N.A.; Langer R.; Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov 2021,20(2),101-124","journal-title":"Nat Rev Drug Discov"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1016\/j.ymthe.2017.03.013","volume":"25","author":"Cullis P.R.","year":"2017","unstructured":"Cullis P.R.; Hope M.J.; Lipid nanoparticle systems for enabling gene therapies. Mol Ther 2017,25(7),1467-1475","journal-title":"Mol Ther"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"120586","DOI":"10.1016\/j.ijpharm.2021.120586","volume":"601","author":"Schoenmaker L.","year":"2021","unstructured":"Schoenmaker L.; Witzigmann D.; Kulkarni J.A.; Verbeke R.; Kersten G.; Jiskoot W.; Crommelin D.J.A.; mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. Int J Pharm 2021,601,120586","journal-title":"Int J Pharm"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1038\/s41565-020-0737-y","volume":"15","author":"Shin M.D.","year":"2020","unstructured":"Shin M.D.; Shukla S.; Chung Y.H.; Beiss V.; Chan S.K.; Ortega-Rivera O.A.; Wirth D.M.; Chen A.; Sack M.; Pokorski J.K.; Steinmetz N.F.; COVID-19 vaccine development and a potential nanomaterial path forward. Nat Nanotechnol 2020,15(8),646-655","journal-title":"Nat Nanotechnol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/d41573-020-00073-5","volume":"19","author":"Thanh Le T.","year":"2020","unstructured":"Thanh Le T.; Andreadakis Z.; Kumar A.; G\u00f3mez Rom\u00e1n R.; Tollefsen S.; Saville M.; Mayhew S.; The COVID-19 vaccine development landscape. Nat Rev Drug Discov 2020,19(5),305-306","journal-title":"Nat Rev Drug Discov"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.omtn.2020.03.015","volume":"20","author":"Chen C.Y.","year":"2020","unstructured":"Chen C.Y.; Tran D.M.; Cavedon A.; Cai X.; Rajendran R.; Lyle M.J.; Martini P.G.V.; Miao C.H.; Treatment of hemophilia A using factor VIII messenger RNA lipid nanoparticles. Mol Ther Nucleic Acids 2020,20,534-544","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"p. 2005641","DOI":"10.1002\/adfm.202005641","volume":"31","author":"Koide H.","year":"2021","unstructured":"Koide H.; Engineering of lipid nanoparticles by the multifunctionalization of the surface with amino acid derivatives for the neutralization of a target toxic peptide. Adv Funct Mater 2021,31(3),p. 2005641","journal-title":"Adv Funct Mater"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"10938","DOI":"10.1021\/acs.chemrev.5b00046","volume":"115","author":"Pattni B.S.","year":"2015","unstructured":"Pattni B.S.; Chupin V.V.; Torchilin V.P.; New developments in liposomal drug delivery. Chem Rev 2015,115(19),10938-10966","journal-title":"Chem Rev"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.addr.2012.09.037","volume":"65","author":"Allen T.M.","year":"2013","unstructured":"Allen T.M.; Cullis P.R.; Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliv Rev 2013,65(1),36-48","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1700375","DOI":"10.1002\/smtd.201700375","volume":"2","author":"Evers M.J.W.","year":"2018","unstructured":"Evers M.J.W.; Kulkarni J.A.; van der Meel R.; Cullis P.R.; Vader P.; Schiffelers R.M.; State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods 2018,2(9),1700375","journal-title":"Small Methods"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1089\/nat.2018.0721","volume":"28","author":"Kulkarni J.A.","year":"2018","unstructured":"Kulkarni J.A.; Cullis P.R.; van der Meel R.; Lipid nanoparticles enabling gene therapies: from concepts to clinical utility. Nucleic Acid Ther 2018,28(3),146-157","journal-title":"Nucleic Acid Ther"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"Adams D.","year":"2018","unstructured":"Adams D.; Gonzalez-Duarte A.; O\u2019Riordan W.D.; Yang C.C.; Ueda M.; Kristen A.V.; Tournev I.; Schmidt H.H.; Coelho T.; Berk J.L.; Lin K.P.; Vita G.; Attarian S.; Plant\u00e9-Bordeneuve V.; Mezei M.M.; Campistol J.M.; Buades J.; Brannagan T.H.; Kim B.J.; Oh J.; Parman Y.; Sekijima Y.; Hawkins P.N.; Solomon S.D.; Polydefkis M.; Dyck P.J.; Gandhi P.J.; Goyal S.; Chen J.; Strahs A.L.; Nochur S.V.; Sweetser M.T.; Garg P.P.; Vaishnaw A.K.; Gollob J.A.; Suhr O.B.; Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018,379(1),11-21","journal-title":"N Engl J Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s40120-020-00208-1","volume":"9","author":"Urits I.","year":"2020","unstructured":"Urits I.; Swanson D.; Swett M.C.; Patel A.; Berardino K.; Amgalan A.; Berger A.A.; Kassem H.; Kaye A.D.; Viswanath O.; A Review of patisiran (ONPATTRO\u00ae) for the treatment of polyneuropathy in people with hereditary transthyretin amyloidosis. Neurol Ther 2020,9(2),301-315","journal-title":"Neurol Ther"},{"key":"ref=14","author":"Stanton M.","unstructured":"Stanton M.; Manganiello M.;  Generation Bio Co, 2022. Non-active lipid nanoparticles with non-viral, capsid free dna. U.S. Patent Application 17\/435,416."},{"key":"ref=15","first-page":"1","volume":"2021","author":"Bailey-Hytholt C.M.","year":"2021","unstructured":"Bailey-Hytholt C.M.; Ghosh P.; Dugas J.; Zarraga I.E.; Bandekar A.; Formulating and characterizing lipid nanoparticles for gene delivery using a microfluidic mixing platform. J Vis Exp 2021,2021(168),1-16","journal-title":"J Vis Exp"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"971","DOI":"10.3389\/fphar.2018.00971","volume":"9","author":"Durymanov M.","year":"2018","unstructured":"Durymanov M.; Reineke J.; Non-viral delivery of nucleic acids: Insight into mechanisms of overcoming intracellular barriers. Front Pharmacol 2018,9,971","journal-title":"Front Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/mt.2010.85","volume":"18","author":"Akinc A.","year":"2010","unstructured":"Akinc A.; Querbes W.; De S.; Qin J.; Frank-Kamenetsky M.; Jayaprakash K.N.; Jayaraman M.; Rajeev K.G.; Cantley W.L.; Dorkin J.R.; Butler J.S.; Qin L.; Racie T.; Sprague A.; Fava E.; Zeigerer A.; Hope M.J.; Zerial M.; Sah D.W.Y.; Fitzgerald K.; Tracy M.A.; Manoharan M.; Koteliansky V.; Fougerolles A.; Maier M.A.; Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol Ther 2010,18(7),1357-1364","journal-title":"Mol Ther"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jconrel.2016.05.059","volume":"235","author":"Chen S.","year":"2016","unstructured":"Chen S.; Tam Y.Y.C.; Lin P.J.C.; Sung M.M.H.; Tam Y.K.; Cullis P.R.; Influence of particle size on the in vivo potency of lipid nanoparticle formulations of siRNA. J Control Release 2016,235,236-244","journal-title":"J Control Release"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ijpharm.2016.06.124","volume":"510","author":"Suzuki Y.","year":"2016","unstructured":"Suzuki Y.; Ishihara H.; Structure, activity and uptake mechanism of siRNA-lipid nanoparticles with an asymmetric ionizable lipid. Int J Pharm 2016,510(1),350-358","journal-title":"Int J Pharm"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.1038\/mtna.2014.61","volume":"3","author":"Kumar V.","year":"2014","unstructured":"Kumar V.; Qin J.; Jiang Y.; Duncan R.G.; Brigham B.; Fishman S.; Nair J.K.; Akinc A.; Barros S.A.; Kasperkovitz P.V.; Shielding of lipid nanoparticles for siRNA delivery: Impact on physicochemical properties, cytokine induction, and efficacy. Mol Ther Nucleic Acids 2014,3(11),e210","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nbt.2612","volume":"31","author":"Gilleron J.","year":"2013","unstructured":"Gilleron J.; Querbes W.; Zeigerer A.; Borodovsky A.; Marsico G.; Schubert U.; Manygoats K.; Seifert S.; Andree C.; St\u00f6ter M.; Epstein-Barash H.; Zhang L.; Koteliansky V.; Fitzgerald K.; Fava E.; Bickle M.; Kalaidzidis Y.; Akinc A.; Maier M.; Zerial M.; Image-based analysis of lipid nanoparticle\u2013mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol 2013,31(7),638-646","journal-title":"Nat Biotechnol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.addr.2019.04.008","volume":"143","author":"Donahue N.D.","year":"2019","unstructured":"Donahue N.D.; Acar H.; Wilhelm S.; Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv Drug Deliv Rev 2019,143,68-96","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.ymthe.2019.02.012","volume":"27","author":"Kowalski P.S.","year":"2019","unstructured":"Kowalski P.S.; Rudra A.; Miao L.; Anderson D.G.; Delivering the messenger: advances in technologies for therapeutic mRNA Delivery. Mol Ther 2019,27(4),710-728","journal-title":"Mol Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3390\/pharmaceutics5030498","volume":"5","author":"Tam Y.","year":"2013","unstructured":"Tam Y.; Chen S.; Cullis P.; Advances in lipid nanoparticles for siRNA delivery. Pharmaceutics 2013,5(4),498-507","journal-title":"Pharmaceutics"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e10213","DOI":"10.1002\/btm2.10213","volume":"6","author":"Schlich M.","year":"2021","unstructured":"Schlich M.; Palomba R.; Costabile G.; Mizrahy S.; Pannuzzo M.; Peer D.; Decuzzi P.; Cytosolic delivery of nucleic acids: The case of ionizable lipid nanoparticles. Bioeng Transl Med 2021,6(2),e10213","journal-title":"Bioeng Transl Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1002\/adhm.201200431","volume":"2","author":"Akita H.","year":"2013","unstructured":"Akita H.; Ishiba R.; Hatakeyama H.; Tanaka H.; Sato Y.; Tange K.; Arai M.; Kubo K.; Harashima H.; A neutral envelope-type nanoparticle containing pH-responsive and SS-cleavable lipid-like material as a carrier for plasmid DNA. Adv Healthc Mater 2013,2(8),1120-1125","journal-title":"Adv Healthc Mater"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"e0241006","DOI":"10.1371\/journal.pone.0241006","volume":"15","author":"Ryals R.C.","year":"2020","unstructured":"Ryals R.C.; Patel S.; Acosta C.; McKinney M.; Pennesi M.E.; Sahay G.; The effects of PEGylation on LNP based mRNA delivery to the eye. PLoS One 2020,15(10),e0241006","journal-title":"PLoS One"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1007\/s11095-012-0874-6","volume":"30","author":"Bao Y.","year":"2013","unstructured":"Bao Y.; Jin Y.; Chivukula P.; Zhang J.; Liu Y.; Liu J.; Clamme J.P.; Mahato R.I.; Ng D.; Ying W.; Wang Y.; Yu L.; Effect of PEGylation on biodistribution and gene silencing of siRNA\/lipid nanoparticle complexes. Pharm Res 2013,30(2),342-351","journal-title":"Pharm Res"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/mt.2009.36","volume":"17","author":"Akinc A.","year":"2009","unstructured":"Akinc A.; Goldberg M.; Qin J.; Dorkin J.R.; Gamba-Vitalo C.; Maier M.; Jayaprakash K.N.; Jayaraman M.; Rajeev K.G.; Manoharan M.; Koteliansky V.; R\u00f6hl I.; Leshchiner E.S.; Langer R.; Anderson D.G.; Development of lipidoid-siRNA formulations for systemic delivery to the liver. Mol Ther 2009,17(5),872-879","journal-title":"Mol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","volume":"15","author":"Cheng Q.","year":"2020","unstructured":"Cheng Q.; Wei T.; Farbiak L.; Johnson L.T.; Dilliard S.A.; Siegwart D.J.; Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR\u2013Cas gene editing. Nat Nanotechnol 2020,15(4),313-320","journal-title":"Nat Nanotechnol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1038\/mtna.2013.66","volume":"2","author":"Mui B.L.","year":"2013","unstructured":"Mui B.L.; Tam Y.K.; Jayaraman M.; Ansell S.M.; Du X.; Tam Y.Y.C.; Lin P.J.C.; Chen S.; Narayanannair J.K.; Rajeev K.G.; Manoharan M.; Akinc A.; Maier M.A.; Cullis P.; Madden T.D.; Hope M.J.; Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol Ther Nucleic Acids 2013,2(12),e139","journal-title":"Mol Ther Nucleic Acids"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"17095","DOI":"10.1021\/jacs.8b08976","volume":"140","author":"Sago C.D.","year":"2018","unstructured":"Sago C.D.; Lokugamage M.P.; Islam F.Z.; Krupczak B.R.; Sato M.; Dahlman J.E.; Nanoparticles that deliver RNA to bone marrow identified by in vivo directed evolution. J Am Chem Soc 2018,140(49),17095-17105","journal-title":"J Am Chem Soc"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1152\/physrev.00002.2012","volume":"93","author":"Bohdanowicz M.","year":"2013","unstructured":"Bohdanowicz M.; Grinstein S.; Role of phospholipids in endocytosis, phagocytosis, and macropinocytosis. Physiol Rev 2013,93(1),69-106","journal-title":"Physiol Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.mam.2006.08.005","volume":"27","author":"Eskelinen E.L.","year":"2006","unstructured":"Eskelinen E.L.; Roles of LAMP-1 and LAMP-2 in lysosome biogenesis and autophagy. Mol Aspects Med 2006,27(5-6),495-502","journal-title":"Mol Aspects Med"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666230403094238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/215396\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1389201024666230403094238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T12:49:51Z","timestamp":1698842991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/215396\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389201024666230403094238","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-10-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}